Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	25 treatment-resistant people	Change from baseline in Simpson-Angus Scale score 12 weeks –1.3 with risperidone (mean dose 4.31 mg/day) –1.64 with quetiapine (mean dose 463.6 mg/day)	P greater-than or equal to 0.05		Not significant
RCT 3-armed trial	25 treatment-resistant people	Change from baseline in weight (kg) 12 weeks –0.65 kg with risperidone (mean dose 4.31 mg/day) –1.2 kg with quetiapine (mean dose 463.6 mg/day)	P greater-than or equal to 0.05		Not significant
RCT 3-armed trial	25 treatment-resistant people	Incidence of dyspepsia 7% with risperidone (mean dose 4.31 mg/day) 8% with quetiapine (mean dose 463.6 mg/day) Absolute numbers not reported	P greater-than or equal to 0.05		Not significant
RCT 3-armed trial	25 treatment-resistant people	Incidence of somnolence 38% with risperidone (mean dose 4.31 mg/day) 25% with quetiapine (mean dose 463.6 mg/day) Absolute numbers not reported	P greater-than or equal to 0.05		Not significant
RCT 3-armed trial	25 treatment-resistant people	Incidence of insomnia 23% with risperidone (mean dose 4.31 mg/day) 25% with quetiapine (mean dose 463.6 mg/day) Absolute numbers not reported	P greater-than or equal to 0.05		Not significant